BFM
KALV

Boothbay Fund Management’s KalVista Pharmaceuticals KALV Stock Holding History

Boothbay Fund Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-142,900
Closed -$1.74M – 2162
2025
Q3 		$1.74M Hold
142,900
– – 0.03% 620
2025
Q2 		$1.62M Buy
+142,900
New +$1.75M 0.03% 550
2021
Q1 		– Sell
-148
Closed -$281K – 1661
2020
Q4 		$281K Buy
+148
New +$2.54K 0.01% 974

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Boothbay Fund Management's KALV Position: Q4 2025 in Review

Boothbay Fund Management sold out of KalVista Pharmaceuticals (KALV) in Q4 2025, closing a stake of 107,283 shares — an estimated $1.31M sold.

Boothbay Fund Management first reported a position in KALV in Q4 2016 and held it in 18 quarters. The position peaked at $2.16M in Q4 2020. 161 funds tracked by Wall St. Rank hold KALV as of Q4 2025.

  • Boothbay Fund Management reported no remaining KalVista Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 107,283 KalVista Pharmaceuticals shares in Q4 2025, an estimated $1.31M.
  • Boothbay Fund Management first reported a position in KalVista Pharmaceuticals in Q4 2016 and held it in 18 quarters.
  • Boothbay Fund Management's KalVista Pharmaceuticals position peaked at $2.16M in Q4 2020.
  • 161 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2025.

Based on Boothbay Fund Management's 13F filing for Q4 2025, filed 17 Feb 2026.